SY
SYVC.US Synovics Pharmaceuticals Inc
- Market cap
- USD 543K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2009.
Is SYVC.US undervalued?
Graham numberThe Graham number of Synovics Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Synovics Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Synovics Pharmaceuticals Inc yet.
Synovics Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Synovics Pharmaceuticals Inc
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States…
Full company profileSynovics Pharmaceuticals Inc financial statements
2009 annualized: Fiscal year 2009 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2009, the balance sheet is the latest quarter. Figures change when the annual report is published.
Synovics Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2000 | 2001 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 134K | 38.0K | 32.0K | 99.0K | 8.19K | 10.5M | 23.5M | 26.0M | 15.0M |
| Gross Profit | 75.0K | 18.0K | - | - | -37.1K | 2.36M | 6.63M | 8.97M | 2.39M |
| Operating Income | - | - | - | - | -1.91M | -3.62M | -10.3M | -2.48M | -6.11M |
| Net Income | - | - | - | - | -2.91M | -8.57M | -20.9M | -4.01M | -7.62M |
| Balance Sheet | |||||||||
| Total Assets | 4.39M | 3.26M | 2.21M | 2.88M | 16.9M | 38.9M | 23.3M | 22.3M | 18.8M |
| Total Liabilities | 2.51M | 2.28M | 3.71M | 3.78M | 5.61M | 25.8M | 31.4M | 17.3M | 19.5M |
| Shareholders' Equity | 1.88M | 982K | -1.50M | -905K | 11.3M | 13.1M | -8.10M | 5.00M | -1.60M |
| Cash & Short-term Investments | 712K | 102K | 3.00K | 629K | 129K | 2.39M | - | 66.0K | 130K |
| Cash Flow | |||||||||
| Operating Cash Flow | - | - | - | - | -2.26M | -5.17M | -2.41M | 3.86M | 989K |
| Capital Expenditure | 3.00K | 0.00 | 0.00 | 4.00K | 238K | 448K | 710K | 708K | 126K |
| Ratios | |||||||||
| ROE | - | - | - | - | -25.8% | -65.4% | - | -80.1% | - |
| ROA | - | - | - | - | -17.2% | -22.0% | -89.4% | -17.9% | -40.6% |
| Net Profit Margin | - | - | - | - | -35,537.8% | -81.5% | -88.9% | -15.4% | -50.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Synovics Pharmaceuticals Inc dividends
Synovics Pharmaceuticals Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:5 on May 30, 2001.
Who owns Synovics Pharmaceuticals Inc
Ownership data of Synovics Pharmaceuticals Inc is not available yet.
Synovics Pharmaceuticals Inc company profile
- Company name
- Synovics Pharmaceuticals Inc
- Ticker
- SYVC.US
- Exchange
- USA Stocks
- Listed since
- Oct 22, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 155
- Fiscal year end
- October
- Address
- 5360 Northwest 35th Avenue, Fort Lauderdale, FL, United States, 33309
- Phone
- 954-486-4590
- Website
- -
About Synovics Pharmaceuticals Inc
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
Synovics Pharmaceuticals Inc management
2- Mr. Jyotindra R. GangeInterim Principal Executive Officer & Director · born 1949
- Mr. John R. PalmerChairman of InCon Technologies Inc.& Incon International Ltd. & CEO of InCon Technologies Inc · born 1943